EUVIMEDEUVIMED entdecken
KorrekturOpen Access

Correction to ‘Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)’

Liver International · 2026-06 · 46 (6)

DOI: 10.1111/liv.70685 ↗

Kurz gefasst

Korrektur in der Zeitschrift Liver International, online erschienen am 09.05.2026. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Correction to ‘Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)’. Liver International, 46(6). https://doi.org/10.1111/liv.70685

Vancouver

Correction to ‘Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)’. Liver International. 2026;46(6). doi:10.1111/liv.70685

BibTeX
@article{euvimed2026,
  title = {Correction to ‘Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real‐World Data From the LOR ‐ HCC (Lombardy Real‐World HCC Group)’},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {6},
  doi = {10.1111/liv.70685}
}
Kostenlos starten →